Sarissa Capital Management LP Long-Term Concentrated

CIK: 0001577524 · Show all filings

Period: Q1 2017 (← Previous) (Next →)

Filing Date: May 15, 2017

Total Value ($000): $253,055 (100.0% shares, 0.0% debt)

Holdings (11)

— MEDICINES CO 33.9%
Value ($000) $85,672 Shares 1,752,000 Est. Cost $29.63 Unrealized —
BIIB BIOGEN INC 33.5%
Value ($000) $84,760 Shares 310,000 Est. Cost $287.35 Unrealized -1.6%
INVA INNOVIVA INC 18.7%
Value ($000) $47,367 Shares 3,425,000 Est. Cost $11.01 Unrealized +7.0%
— NOVELION THERAPEUTICS INC 4.4%
Value ($000) $11,008 Shares 1,025,000 Est. Cost $8.42 Unrealized —
— BIOVERATIV INC 3.3%
Value ($000) $8,441 Shares 155,000 Est. Cost $54.46 Unrealized —
— INTRA CELLULAR THERAPIES INC 2.3%
Value ($000) $5,850 Shares 360,000 Est. Cost $27.96 Unrealized —
— APRICUS BIOSCIENCES INC 1.2%
Value ($000) $3,055 Shares 1,447,906 Est. Cost $1.30 Unrealized —
— VIVUS INC 1.1%
Value ($000) $2,882 Shares 2,573,943 Est. Cost $9.08 Unrealized —
— ADVAXIS INC 1.1%
Value ($000) $2,771 Shares 339,180 Est. Cost $8.09 Unrealized —
ABBV ABBVIE INC. 0.3%
Value ($000) $651 Shares 10,000 Est. Cost $38.85 Unrealized +11.9%
— AVEO PHARMACEUTICALS INC 0.2%
Value ($000) $598 Shares 1,013,616 Est. Cost $1.84 Unrealized —